Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ov... by Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Geoffrey I Shapiro, Stephanie K Dougan, Nabihah Tayob, Joyce F Liu, Khanh Do, Heather Parsons, Molly DiLullo, Eileen Wrabel, Lestat R Ali, Ana C Garrido-Castro, Noah Graham, Christina Herold, Jennifer Desrosiers, Shom Goel, Amy J Williams

Get full text